Description
Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB) looks ahead to Wednesday's analyst and investor meeting which is being held in New York and urges interested UK shareholders to get involved.Lumsden also talks through a big bit of news they received this week from the US Food & Drug Administration - their lead drug has been granted orphan designation.This status, which qualifies the antibiotic iclaprim for certain incentives including tax breaks, is for a very narrow indication: the treatment of cystic fibrosis patients with Staphylococcus aureus lung infections.
Tags
motifbio graham lumsden motif bio